Literature DB >> 18023944

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.

Martin O C Ota1, Roger H Brookes, Philip C Hill, Patrick K Owiafe, Hannah B Ibanga, Simon Donkor, Timothy Awine, Helen McShane, Richard A Adegbola.   

Abstract

Understanding the immunogenicity of BCG in a population where it has failed will facilitate the design of new TB vaccines. We assessed the immunogenicity of M. bovis BCG over 12 months by ELISPOT assay. Forty-one adolescents and young Gambian male adults received a tuberculin skin test (TST) which was followed one week later by BCG vaccination, but the 23 control subjects received neither of these. TST alone significantly induced PPD-specific IFN-gamma producing cells. Twenty-three percent of subjects did not respond to BCG, which was associated with higher pre-existing ex vivo response to PPD. Paradoxically, amongst BCG responders there was a correlation between pre-existing response and subsequent response to BCG. We conclude that BCG is immunogenic, but this effector response is short-lived and can be limited in higher pre-existing anti-mycobacterial immunity, suggesting a possible threshold beyond which BCG immunogenicity is inhibited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023944     DOI: 10.1016/j.vaccine.2007.10.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults.

Authors:  Mardi C Boer; Corine Prins; Krista E van Meijgaarden; Jaap T van Dissel; Tom H M Ottenhoff; Simone A Joosten
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

2.  Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.

Authors:  Niannian Ji; Neelam Mukherjee; Edwin E Morales; Maggie E Tomasini; Vincent Hurez; Tyler J Curiel; Getahun Abate; Dan F Hoft; Xiang-Ru Zhao; Jon Gelfond; Sourindra Maiti; Laurence J N Cooper; Robert S Svatek
Journal:  Oncoimmunology       Date:  2019-05-25       Impact factor: 8.110

3.  Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Authors:  Birgit Korioth-Schmitz; Casey C Perley; Jaimie D Sixsmith; Eva M Click; Sunhee Lee; Norman L Letvin; Richard Frothingham
Journal:  Vaccine       Date:  2015-07-17       Impact factor: 3.641

4.  Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations.

Authors:  Shu Zhang; Lingyun Shao; Ling Mo; Jiazhen Chen; Feifei Wang; Chengyan Meng; Min Zhong; Lihua Qiu; Meiying Wu; Xinhua Weng; Wenhong Zhang
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 5.  Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?

Authors:  Sarman Singh; Manoj Kumar; Pragati Singh
Journal:  Tuberc Res Treat       Date:  2015-01-28

6.  Is TB Testing Associated With Increased Blood Interferon-Gamma Levels?

Authors:  Aideen E Kennedy; Jim O'Mahony; Noel Byrne; John MacSharry; Riona G Sayers
Journal:  Front Vet Sci       Date:  2017-10-23

7.  Diagnostics of tuberculosis and differentiation of nonspecific tuberculin reactions in animals.

Authors:  Sovetzhan Z Basybekov; Marat B Bazarbayev; Bolat A Yespembetov; Assiya Mussaeva; Serik G Kanatbayev; Kanapya M Romashev; Aigul K Dossanova; Tokseiit A Yelekeyev; Elmira K Akmatova; Nazym S Syrym
Journal:  Braz J Microbiol       Date:  2017-10-25       Impact factor: 2.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.